Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
DDW Highlights: 17 February 2026
In this 16‑minute DDW Highlights episode, host Bruno Quinney recaps five major drug‑discovery stories from the past week, focusing on a breakthrough study linking specific biomarkers to improved cancer survival rates and the launch of a multinational consortium tackling chronic kidney disease. He also touches on regulatory updates, emerging AI tools for target identification, and notable funding announcements in biotech. Quinney’s narration underscores the clinical relevance of the cancer findings and the collaborative potential of the kidney disease initiative, while highlighting how these developments could accelerate therapeutic pipelines.
Half of Americans Believe only the Rich Can Afford GLP-1s without Insurance
A ValuePenguin study finds that a median‑income American household would need to allocate about 7.3% of earnings to afford a two‑milligram monthly supply of Ozempic, the flagship GLP‑1 weight‑loss drug. In the poorest states, the cost can approach one‑tenth of...
Tanaka Establishes Total Solutions System for Contract Manufacturing of Diagnostics
Tanaka Precious Metal Technologies has built a total‑solution system for contract manufacturing of in‑vitro diagnostic test kits, adding dedicated dispensing and packaging lines for extraction buffer. The new infrastructure lets the company handle every step—from assay development to final product...
FDA's New Move Undermines mRNA Flu Vaccine
https://open.substack.com/pub/pauloffit/p/weaponizing-the-fda-against-vaccines?utm_campaign=post-expanded-share&utm_medium=web A closer look at the FDA's recent kill shot against an mRNA influenza vaccine.
The Honest Broker in Pediatrics: Building the Medical Home
Dr. Ronald L. Lindsay recounts how he built a fully operational pediatric medical home at a regional military hospital in just two and a half years, delivering 24/7 care to vulnerable children from worldwide military families. His interdisciplinary developmental‑behavioral clinic...
Dual Wielding in I&I: A Pivotal Year Ahead
The article argues that the next breakthrough in immunology and inflammation (I&I) therapeutics will come from multi‑drug and multi‑target strategies rather than single‑target antibodies, which have hit an efficacy ceiling. It traces the evolution from early blockbuster biologics like Humira...
Newman Explains How Sanford Health Is Virtually Rewriting the Rural Health Playbook
Dave Newman, MD, Chief Medical Officer of Virtual Care at Sanford Health, explains how the system’s expansive virtual care program—spanning 78 specialties across 300,000 square miles—has become essential for rural patients, saving them an average of 176 miles per visit....
IT Execs Seek to Tame Application Sprawl Without Stifling Innovation Through Shared Governance
In a healthsystemCIO webinar, senior IT leaders from RWJBarnabas Health, Ardent Health Services, and the University of Maryland Medical System discussed how to manage the flood of application requests while fostering innovation. They emphasized establishing a single, standardized intake point,...
STAT+: Ocular’s Experimental Eye Drug Beats Low Dose of Regeneron’s Eylea in Late-Stage Trial
Ocular Therapeutix announced that its experimental drug Axpaxli met the primary endpoint in a Phase 3 trial for wet age‑related macular degeneration, maintaining vision in 74% of patients at nine months and 66% at one year after a single injection....
Ambiguous CPT Codes Threaten Physicians with Criminal Charges
I interviewed a dual-boarded psychiatrist and internist who warns that the ambiguity of CPT codes is being used to criminalize physicians. Dr. Muhamad Aly Rifai joined me to discuss the chilling case of Dr. Ron Elfenbein. During the COVID-19 pandemic, Dr. Elfenbein...
Size‐Transformable Supramolecular Nanoprodrugs Enable Redox Imbalance Amplification and Cholesterol Modulation to Boost Multidimensional Tumor Immunotherapy
Researchers have engineered a tumor‑targeting, tumor‑microenvironment‑responsive supramolecular nanoprodrug that switches size to enhance deep tumor penetration. The nanoprodrug simultaneously induces redox imbalance—accumulating reactive nitrogen species and depleting glutathione—to amplify ferroptosis, while depleting cholesterol to rejuvenate exhausted T cells. This multidimensional...
PH‐Responsive Nanoparticle‐Coated Calcium Phosphate Granules for Bone Cancer Therapy
Researchers have engineered β‑tricalcium phosphate (β‑TCP) granules coated with selenium‑doped mesoporous silica nanoparticles (SeMIA) linked via pH‑responsive imine–alendronate bonds. The imine linkers remain stable at physiological pH but cleave in the mildly acidic osteosarcoma microenvironment, releasing nanoparticles that selectively kill...
Airglove Medical Announces Major Breakthrough in Difficult Venous Access
Airglove Medical has launched Airglove v2, an air‑warming glove designed to improve vein physiology before venepuncture. Clinical evaluations across more than 150 UK hospitals reported an 87.5% first‑time cannulation rate in oncology patients, a group known for difficult IV access. The...
Suspendable and Scalable Ultrasound‐Actuated ZnO‐Nanosheet‐Based Piezoelectric Microdevices for Wireless Electrical Stimulation of Cells
Researchers have created subcellular-sized, silicon‑based microdevices that incorporate ZnO nanosheets to act as piezoelectric generators. When deformed by cellular forces or external ultrasound within the biomedical range, these nanostructures produce localized electrical potentials that depolarize cell membranes and trigger calcium...
STAT+: Compass Says Its Psilocybin Drug Helped Patients with Severe Depression in Two Trials
Compass Pathways announced that its synthetic psilocybin therapy, COMP360, achieved statistically significant improvements in two identical Phase 3 trials for severe major depressive disorder. Both studies met primary endpoints, showing greater reduction in depression scores than placebo‑controlled psychotherapy. The data suggest...
Future Docs Must Master Digital Health and AI
I'll give a presentation today to medical students at Semmelweis Medical School about the rise of digital health and AI, as part of the 𝐷𝑖𝑠𝑟𝑢𝑝𝑡𝑖𝑣𝑒 𝑇𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑖𝑒𝑠 𝑖𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 course that I co-launched. 𝐈𝐟 𝐭𝐡𝐞𝐫𝐞 𝐢𝐬 𝐨𝐧𝐞 𝐦𝐞𝐬𝐬𝐚𝐠𝐞 𝐲𝐨𝐮 𝐰𝐨𝐮𝐥𝐝 𝐫𝐞𝐚𝐥𝐥𝐲 𝐥𝐢𝐤𝐞...
Queen Victoria Hospital Paves the Digital Way for Treating Patients in Minor Injuries Unit
Queen Victoria Hospital NHS Foundation Trust has rolled out the Archie electronic patient record (EPR) system in its Minor Injuries Unit (MIU), marking a rapid digital transformation. Within three months, the MIU recorded 16,465 annual patient visits and achieved a...
Welltower / Multiple Care Homes Merger Inquiries
The UK Competition and Markets Authority (CMA) has opened a phase‑1 merger inquiry into Welltower Inc.’s recent acquisition of more than 600 care homes from Barchester, HC‑One, Aria Care and Danforth Care. The regulator has already served initial enforcement orders...
The German Digital Healthcare Act (DVG) at Seven Years: Review of the DiGA Ecosystem and Its Impact on European Health...
Seven years after Germany’s Digital Healthcare Act (DVG) introduced the world’s first reimbursement pathway for digital health apps, the DiGA ecosystem has matured from speculative beginnings to a €234 million market serving nearly one million prescriptions. The fast‑track approval process accelerated...
Strategic Commissioning Plan for Leicestershire and Northamptonshire ICBs Notes Digital to Transform Population Health, Neighbourhood Health, and Prevention
The Leicester, Leicestershire and Rutland ICB and Northamptonshire ICB have released a five‑year strategic commissioning plan to 2031 that places digital and data at the core of population health, neighbourhood health and prevention initiatives. A new digital and data strategy...
Revolutionizing Healthcare: The Transformative Impact of Artificial Intelligence
Artificial intelligence is moving from hype to concrete healthcare applications, as highlighted in a new AIAInow session featuring Stanford Medicine and Starkey Hearing. The event showcases AI’s role in diagnostics, where neural networks now exceed human specialists, and the transformation...
Selecting the Optimal Cell Therapy Manufacturing Platform
Developers of cell and gene therapies must choose between fully integrated turnkey platforms and modular, multi‑device systems. Integrated solutions deliver rapid time‑to‑value and simplified workflows, ideal for low‑volume autologous products, but they restrict reagent flexibility and scale. Modular platforms provide...
How to Evaluate Prospective Diagnostic Laboratory Partners for Your Patient Support Program
The pharmaceutical industry now invests over $5 billion annually in patient support programs (PSPs), which boost adherence by roughly 30 % and lower overall healthcare costs. Diagnostic laboratory testing is a cornerstone of these programs, delivering timely data that guides dosing, monitors...
Listen: Why Do I Need Prior Authorization?
Prior authorization is a pre‑approval step insurers require before covering a prescription or treatment. The criteria triggering a request remain opaque, turning even routine care into a paperwork marathon for physicians. Patients often endure delays, risking condition worsening while providers...
Case Study: University Hospitals of Northamptonshire Optimising Clinical Pathways Through Digital
University Hospitals of Northamptonshire partnered with Isla Health to digitise and re‑engineer clinical pathways across 15 specialties, eliminating manual bottlenecks. The overhaul slashed paediatric epilepsy processing from three days to ten minutes and cut pain‑management referral times from eight days...
CStone Secures FDA Clearance to Begin CS2009 Phase II Trial
CStone Pharmaceuticals has secured FDA clearance for its investigational new drug application, allowing the launch of a Phase II trial of CS2009, a trispecific antibody that simultaneously targets PD‑1, VEGFA and CTLA‑4. The global study uses a parallel, multi‑cohort expansion design...
ExCellThera Secures German NUB Status 1 Listing for Zemcelpro
ExCellThera and its subsidiary Cordex Biologics have secured a Status 1 listing under Germany’s NUB programme for their cell therapy Zemcelpro (dorocubicel). The therapy, which received conditional marketing authorisation from the European Commission, targets adults with haematological malignancies lacking suitable donor...
STAT+: As China’s Drug Industry Races Ahead, Its GLP-1 Race Is Accelerating Too
China’s pharmaceutical sector is rapidly expanding, now generating its own GLP‑1 drugs alongside imported treatments. Novo Nordisk reported a 5% decline in Ozempic sales in China last year, the first dip since its 2021 launch, while sales grew elsewhere. The...
No‑Compression Breast CT Approved, Yet Still Rare
Pain that comes from mammography has been a common challenge in screening. But what if a device can change that experience? Here is a no-compression breast CT. As far as I know, no-compression dedicated breast CTs like the Koning Vera exist...
Data-Driven Digital Health Businesses Challenged with Balancing AI Advances and Tighter Regulation in 2026
Digital health firms in 2026 face a sharp tension between accelerating AI capabilities and tightening data regulations across the UK and EU. Hyper‑personalised care, driven by wearables and AI‑powered NHS apps, promises better outcomes but raises compliance challenges. New frameworks...
Learn the ABCs of Medicare, Ep293
In this episode Ryan Morrissey breaks down the essentials of Medicare for listeners approaching age 65, covering Parts A, B, C, and D, associated costs, and the critical timing of enrollment to avoid penalties. He explains the differences between original...
Sofia Noori, Nema Health
Nema Health announced that its intensive cognitive processing therapy (ICPT) achieved a reported 99% cure rate for post‑traumatic stress disorder (PTSD) within a month, according to a new study. The findings were presented by CEO and psychiatrist Sofia Noori, who...
Sources: US Healthcare Manufacturer Danaher Is Nearing a Deal to Buy Medtech Company Masimo for ~$10B; Masimo Is in an...
Danaher, a US healthcare conglomerate, is close to finalizing a roughly $10 billion acquisition of Masimo, the maker of pulse‑oximetry and other medical monitoring devices. The deal, still subject to antitrust clearance, would add Masimo’s sensor technology to Danaher’s Life Sciences...
Biopharma Must Cope With The Fetal Bovine Serum Squeeze
Biopharma faces a tightening fetal bovine serum (FBS) market as U.S. cattle inventories hit record lows and European disease outbreaks curb supply. Prices have surged more than 300% over five years and release timelines have lengthened from weeks to months...
Red Light Therapy Shows Promise for Treating Brain Injuries
A University of Utah Health study examined red‑light photobiomodulation (PBM) as a preventive therapy for repetitive head acceleration events in collegiate football. Twenty‑six Division I athletes were randomized to active or sham transcranial and intranasal PBM over 16 weeks, receiving three...
Paras Health Appoints Balkishan Sharma as CHRO
Paras Health has appointed Balkishan Sharma as chief human resources and business transformation officer, a move that underscores the network’s drive toward operational excellence and growth. Sharma returns after a six‑year stint with the group and brings more than 18...
Radiologists Urge Cigna to Rescind Coverage Restriction for Key Imaging Procedure
Radiology societies, led by the Society of Interventional Radiology, have asked Cigna to reverse policy 0539, which labels implantable peripheral nerve stimulation (PNS) for chronic pain as medically unnecessary. The groups cite robust randomized trials, FDA clearance, and a favorable...
Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...
Congress renewed the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program, extending it to September 30 2029 and eliminating the dual sunset dates. The FDA released its Rare Disease Innovation Hub’s 2026 Strategic Agenda, allocating $1 million in funding and outlining plans...
HTML Comments Reveal Vendor’s Intentional Export Method Distinction
Your human users might only read the visible content in your page, but bots read the HTML comments :-) I appreciated this nugget from my EHI Export analysis, and I have to say that I agree with "kendra/sli", they had...
Question Sensational Medical Claims; Scientists Must Champion Truth
Be aware there is a rising number of posts using blatantly false medical & scientific information, with misquoted and twisted interpretations of articles, taking videos by others without permission and warping the facts to suit their own purposes, and making...
Montana Hospital Restores Phones as Cyber-Related Network Disruptions Persist
Livingston HealthCare in Montana announced that its phone system has been fully restored after a recent cybersecurity incident forced the hospital to shut down communications and other network services. The disruption, first reported on Feb. 13, stemmed from a potential...
Bispecific Autoimmune Therapies Set to Transform 2024
"Dual Wielding in I&I: A Pivotal Year Ahead" - new blog - Atlas EIR Cody Tranbarger with a tour de force on the bispecific opportunities in autoimmune... https://t.co/StQJX0vgfx
Koushicare Device Offers Relief for Dry Eye
Can you guess what this device is for? It is made by Koushicare, and it helps people with dry eye. https://t.co/FilgMQ1JEy
Brain Differences Between Sexes Get More Pronounced From Puberty
A new preprint analyzing fMRI data from 1,286 participants aged 8‑100 finds that sex differences in brain connectivity are minimal in childhood but expand sharply at puberty and continue diverging into adulthood. Using an AI model called Krakencoder, researchers identified...
GSK
#GSK Exdensur (depemokimab) approved in EU for treating "severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps". Follows from the SWIFT and ANCHOR phase III trials.
Danaher Nears $10 B Acquisition of Masimo
Big deal scoop by @sindap and @mroliverbarnes - US healthcare manufacturer Danaher is closing in a $10bn deal to buy medical tech group Masimo. A deal could be announced as early as Tuesday provided it does not hit any last-minute...
Epic's AI Road Map Should Concern Insurers
Epic Systems, which commands over 35% of the U.S. hospital IT market, is extending its AI capabilities into the payer space through a stack that relies heavily on Microsoft Azure and OpenAI. The article warns that this architectural dependency creates...
Plasmid Injection Triggers Immune Attack on Cancer Survival Protein
What if a physician could inject you with a plasmid that would induce an immune response against a protein needed for cancer cell survival? This novel strategy is being tested and looks promising for refractory cancers. Talking Biotech 488 ...
Free, Ad‑free Biomed Insights Reaching 200k Globally
Ground Truths are free essays and podcasts on the hot topics in biomedicine and health. Mostly things the media doesn't cover or adequately highlight. No ads or sponsors. Join ~200,000 subscribers from 212 countries https://t.co/ZgnO2Y0P4L
FastFinance: Cost Implications of New HOPD Reporting Rules; Election Year Opportunity on Affordability
HFMA’s FastFinance podcast highlights new off‑campus HOPD reporting requirements that could impose significant cost burdens on health systems. The episode also cites a "Weird Number"—a 3‑5% annual net revenue loss attributed to inefficient electronic health records and billing platforms. Additionally,...